JP2015502335A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015502335A5 JP2015502335A5 JP2014536287A JP2014536287A JP2015502335A5 JP 2015502335 A5 JP2015502335 A5 JP 2015502335A5 JP 2014536287 A JP2014536287 A JP 2014536287A JP 2014536287 A JP2014536287 A JP 2014536287A JP 2015502335 A5 JP2015502335 A5 JP 2015502335A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- diamine
- trans
- cyclopropyl
- halo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 100
- 125000005843 halogen group Chemical group 0.000 claims 80
- 150000001875 compounds Chemical class 0.000 claims 49
- 125000003545 alkoxy group Chemical group 0.000 claims 47
- 239000008194 pharmaceutical composition Substances 0.000 claims 34
- 229910052739 hydrogen Inorganic materials 0.000 claims 33
- 239000001257 hydrogen Substances 0.000 claims 33
- 125000004122 cyclic group Chemical group 0.000 claims 32
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 27
- 125000004432 carbon atom Chemical group C* 0.000 claims 23
- 125000000623 heterocyclic group Chemical group 0.000 claims 23
- 125000000753 cycloalkyl group Chemical group 0.000 claims 22
- 125000005842 heteroatom Chemical group 0.000 claims 20
- 229940124530 sulfonamide Drugs 0.000 claims 18
- 125000002947 alkylene group Chemical group 0.000 claims 17
- 125000001072 heteroaryl group Chemical group 0.000 claims 17
- 150000002431 hydrogen Chemical group 0.000 claims 17
- 229910052760 oxygen Inorganic materials 0.000 claims 17
- 229910052717 sulfur Inorganic materials 0.000 claims 17
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 16
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 16
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 16
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 16
- 125000002252 acyl group Chemical group 0.000 claims 16
- 125000003342 alkenyl group Chemical group 0.000 claims 16
- 125000000304 alkynyl group Chemical group 0.000 claims 16
- 125000003118 aryl group Chemical group 0.000 claims 16
- 239000004202 carbamide Substances 0.000 claims 16
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 16
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 16
- 150000003456 sulfonamides Chemical class 0.000 claims 16
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 16
- 125000004093 cyano group Chemical group *C#N 0.000 claims 13
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 12
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims 12
- -1 cyano, sulfinyl Chemical group 0.000 claims 10
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 8
- 125000005647 linker group Chemical group 0.000 claims 7
- 239000012453 solvate Substances 0.000 claims 7
- 125000001424 substituent group Chemical group 0.000 claims 7
- 229920006395 saturated elastomer Polymers 0.000 claims 6
- 125000002837 carbocyclic group Chemical group 0.000 claims 5
- VKIRRGRTJUUZHS-UHFFFAOYSA-N cyclohexane-1,4-diamine Chemical compound NC1CCC(N)CC1 VKIRRGRTJUUZHS-UHFFFAOYSA-N 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 238000011282 treatment Methods 0.000 claims 5
- ZSPRVNGZTHEJRR-UHFFFAOYSA-N 2-[(2-phenylcyclopropyl)amino]cycloheptan-1-ol Chemical compound OC1CCCCCC1NC1C(C=2C=CC=CC=2)C1 ZSPRVNGZTHEJRR-UHFFFAOYSA-N 0.000 claims 4
- GNHAGFMFRYWQQD-UHFFFAOYSA-N 2-[(2-phenylcyclopropyl)amino]cyclopentan-1-ol Chemical compound OC1CCCC1NC1C(C=2C=CC=CC=2)C1 GNHAGFMFRYWQQD-UHFFFAOYSA-N 0.000 claims 4
- 150000001408 amides Chemical class 0.000 claims 4
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 4
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- 125000004434 sulfur atom Chemical group 0.000 claims 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- BINXOHRETRQOCW-NSKBAKJYSA-N 4-n-[(1r,2s)-2-[4-[3-(trifluoromethyl)phenyl]phenyl]cyclopropyl]cyclohexane-1,4-diamine Chemical compound C1CC(N)CCC1N[C@H]1[C@H](C=2C=CC(=CC=2)C=2C=C(C=CC=2)C(F)(F)F)C1 BINXOHRETRQOCW-NSKBAKJYSA-N 0.000 claims 2
- ALHBJBCQLJZYON-PFSRBDOWSA-N 4-n-[(1r,2s)-2-phenylcyclopropyl]cyclohexane-1,4-diamine Chemical compound C1CC(N)CCC1N[C@H]1[C@H](C=2C=CC=CC=2)C1 ALHBJBCQLJZYON-PFSRBDOWSA-N 0.000 claims 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- ALHBJBCQLJZYON-ZQDZILKHSA-N iadademstat Chemical compound C1C[C@@H](N)CC[C@@H]1N[C@H]1[C@H](C=2C=CC=CC=2)C1 ALHBJBCQLJZYON-ZQDZILKHSA-N 0.000 claims 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims 2
- 238000011321 prophylaxis Methods 0.000 claims 2
- 125000006239 protecting group Chemical group 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- HEOKXBMRYSEMPZ-ARZKPCJCSA-N (3r)-1-[4-[[(1r,2s)-2-phenylcyclopropyl]amino]cyclohexyl]pyrrolidin-3-amine Chemical compound C1[C@H](N)CCN1C1CCC(N[C@H]2[C@@H](C2)C=2C=CC=CC=2)CC1 HEOKXBMRYSEMPZ-ARZKPCJCSA-N 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- DKSPTOGWVCYBTE-SJJHQCBESA-N 1-ethyl-3-[4-[[(1r,2s)-2-phenylcyclopropyl]amino]cyclohexyl]urea Chemical compound C1CC(NC(=O)NCC)CCC1N[C@H]1[C@H](C=2C=CC=CC=2)C1 DKSPTOGWVCYBTE-SJJHQCBESA-N 0.000 claims 1
- XWEAHNZIYFXBRU-PWUWZPNHSA-N 1-methyl-4-n-[(1r,2s)-2-phenylcyclopropyl]cyclohexane-1,4-diamine Chemical compound C1CC(C)(N)CCC1N[C@H]1[C@H](C=2C=CC=CC=2)C1 XWEAHNZIYFXBRU-PWUWZPNHSA-N 0.000 claims 1
- VGIBKSPLCIONPK-ZYKFHVCXSA-N 1-n-[(1r,2s)-2-(4-phenylmethoxyphenyl)cyclopropyl]cyclobutane-1,3-diamine Chemical compound C1C(N)CC1N[C@H]1[C@H](C=2C=CC(OCC=3C=CC=CC=3)=CC=2)C1 VGIBKSPLCIONPK-ZYKFHVCXSA-N 0.000 claims 1
- IXCIBKGJACVRSZ-WZOJCFFYSA-N 1-n-[(1r,2s)-2-[4-[3-(trifluoromethyl)phenyl]phenyl]cyclopropyl]cyclobutane-1,3-diamine Chemical compound C1C(N)CC1N[C@H]1[C@H](C=2C=CC(=CC=2)C=2C=C(C=CC=2)C(F)(F)F)C1 IXCIBKGJACVRSZ-WZOJCFFYSA-N 0.000 claims 1
- MDWANQHRPJNECZ-IFWUJCSASA-N 1-n-[(1r,2s)-2-phenylcyclopropyl]cyclobutane-1,3-diamine Chemical compound C1C(N)CC1N[C@H]1[C@H](C=2C=CC=CC=2)C1 MDWANQHRPJNECZ-IFWUJCSASA-N 0.000 claims 1
- ZWMGUAYLVFCVEL-PFSRBDOWSA-N 1-n-[(1r,2s)-2-phenylcyclopropyl]cyclohexane-1,3-diamine Chemical compound C1C(N)CCCC1N[C@H]1[C@H](C=2C=CC=CC=2)C1 ZWMGUAYLVFCVEL-PFSRBDOWSA-N 0.000 claims 1
- XGMDPYBRLXQSMT-ZYFYDLNSSA-N 1-n-methyl-4-n-[(1r,2s)-2-(4-phenylmethoxyphenyl)cyclopropyl]cyclohexane-1,4-diamine Chemical compound C1CC(NC)CCC1N[C@H]1[C@H](C=2C=CC(OCC=3C=CC=CC=3)=CC=2)C1 XGMDPYBRLXQSMT-ZYFYDLNSSA-N 0.000 claims 1
- QWNIVCMUMLGQPC-QZNJRLLKSA-N 1-n-methyl-4-n-[(1r,2s)-2-[4-[3-(trifluoromethyl)phenyl]phenyl]cyclopropyl]cyclohexane-1,4-diamine Chemical compound C1CC(NC)CCC1N[C@H]1[C@H](C=2C=CC(=CC=2)C=2C=C(C=CC=2)C(F)(F)F)C1 QWNIVCMUMLGQPC-QZNJRLLKSA-N 0.000 claims 1
- ZRCDNYZZNYQDNU-SSHXOBKSSA-N 1-n-methyl-4-n-[(1r,2s)-2-phenylcyclopropyl]cyclohexane-1,4-diamine Chemical compound C1CC(NC)CCC1N[C@H]1[C@H](C=2C=CC=CC=2)C1 ZRCDNYZZNYQDNU-SSHXOBKSSA-N 0.000 claims 1
- SGJAFQRGQIADTL-UHFFFAOYSA-N 2-[(2-phenylcyclopropyl)amino]cyclohexan-1-ol Chemical compound OC1CCCCC1NC1C(C=2C=CC=CC=2)C1 SGJAFQRGQIADTL-UHFFFAOYSA-N 0.000 claims 1
- CFJSUYCTFMMNPF-RRIIRSAJSA-N 3-[4-[(1s,2r)-2-[(4-aminocyclohexyl)amino]cyclopropyl]phenyl]phenol Chemical compound C1CC(N)CCC1N[C@H]1[C@H](C=2C=CC(=CC=2)C=2C=C(O)C=CC=2)C1 CFJSUYCTFMMNPF-RRIIRSAJSA-N 0.000 claims 1
- JTYCUBANCFAWDT-BCAXMMLOSA-N 3-[5-[(1r,2r)-2-[(4-aminocyclohexyl)amino]cyclopropyl]-1,3-thiazol-2-yl]phenol Chemical compound C1CC(N)CCC1N[C@H]1[C@H](C=2SC(=NC=2)C=2C=C(O)C=CC=2)C1 JTYCUBANCFAWDT-BCAXMMLOSA-N 0.000 claims 1
- SJYSQOJGPMLVJQ-GMGZGELVSA-N 3-[5-[(1r,2r)-2-[(4-aminocyclohexyl)amino]cyclopropyl]thiophen-2-yl]phenol Chemical compound C1CC(N)CCC1N[C@H]1[C@H](C=2SC(=CC=2)C=2C=C(O)C=CC=2)C1 SJYSQOJGPMLVJQ-GMGZGELVSA-N 0.000 claims 1
- LNGPHSIKIPBXBM-KLXIGZAZSA-N 3-[5-[(1s,2r)-2-[(4-aminocyclohexyl)amino]cyclopropyl]pyridin-2-yl]-5-methoxybenzonitrile Chemical compound COC1=CC(C#N)=CC(C=2N=CC(=CC=2)[C@H]2[C@@H](C2)NC2CCC(N)CC2)=C1 LNGPHSIKIPBXBM-KLXIGZAZSA-N 0.000 claims 1
- NKOGAETYSHVEAL-ZYKFHVCXSA-N 3-[[5-[(1s,2r)-2-[(4-aminocyclohexyl)amino]cyclopropyl]pyridin-2-yl]amino]benzonitrile Chemical compound C1CC(N)CCC1N[C@H]1[C@H](C=2C=NC(NC=3C=C(C=CC=3)C#N)=CC=2)C1 NKOGAETYSHVEAL-ZYKFHVCXSA-N 0.000 claims 1
- VQPAGQIHCBZNFI-UUYZCOGDSA-N 3-n-[(1r,2s)-2-(4-phenylmethoxyphenyl)cyclopropyl]-2,3-dihydro-1h-indene-1,3-diamine Chemical compound C1=CC([C@@H]2C[C@H]2NC2CC(C3=CC=CC=C32)N)=CC=C1OCC1=CC=CC=C1 VQPAGQIHCBZNFI-UUYZCOGDSA-N 0.000 claims 1
- CXVNDANAZJDMPI-RFQWIFLJSA-N 3-n-[(1r,2s)-2-[4-[3-(trifluoromethyl)phenyl]phenyl]cyclopropyl]-2,3-dihydro-1h-indene-1,3-diamine Chemical class C1=CC([C@@H]2C[C@H]2NC2CC(C3=CC=CC=C32)N)=CC=C1C1=CC=CC(C(F)(F)F)=C1 CXVNDANAZJDMPI-RFQWIFLJSA-N 0.000 claims 1
- ZFWZJXPRYBXQIV-PBHCIXSXSA-N 3-n-[(1r,2s)-2-phenylcyclopropyl]-2,3-dihydro-1h-indene-1,3-diamine Chemical compound C1([C@@H]2C[C@H]2NC2CC(C3=CC=CC=C32)N)=CC=CC=C1 ZFWZJXPRYBXQIV-PBHCIXSXSA-N 0.000 claims 1
- LZDNSUQSFKCUBO-DISOXQEGSA-N 4-(aminomethyl)-n-[(1r,2s)-2-phenylcyclopropyl]cyclohexan-1-amine Chemical compound C1CC(CN)CCC1N[C@H]1[C@H](C=2C=CC=CC=2)C1 LZDNSUQSFKCUBO-DISOXQEGSA-N 0.000 claims 1
- OBDZEWSPDTWTEU-UHFFFAOYSA-N 4-[2-[(4-aminocyclohexyl)amino]cyclopropyl]phenol Chemical compound C1CC(N)CCC1NC1C(C=2C=CC(O)=CC=2)C1 OBDZEWSPDTWTEU-UHFFFAOYSA-N 0.000 claims 1
- RDWRYLVZMRPAAI-QQGUTBHFSA-N 4-[[(1r,2s)-2-[6-[3-(trifluoromethyl)phenyl]pyridin-3-yl]cyclopropyl]amino]cyclohexan-1-ol Chemical compound C1CC(O)CCC1N[C@H]1[C@H](C=2C=NC(=CC=2)C=2C=C(C=CC=2)C(F)(F)F)C1 RDWRYLVZMRPAAI-QQGUTBHFSA-N 0.000 claims 1
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims 1
- KELVXSSXVHPRDE-WZOJCFFYSA-N 4-morpholin-4-yl-n-[(1r,2s)-2-phenylcyclopropyl]cyclohexan-1-amine Chemical compound N([C@@H]1C[C@H]1C=1C=CC=CC=1)C(CC1)CCC1N1CCOCC1 KELVXSSXVHPRDE-WZOJCFFYSA-N 0.000 claims 1
- YCAWTMXHBSTPQD-UHFFFAOYSA-N 4-n-(2-methyl-2-phenylcyclopropyl)cyclohexane-1,4-diamine Chemical compound C=1C=CC=CC=1C1(C)CC1NC1CCC(N)CC1 YCAWTMXHBSTPQD-UHFFFAOYSA-N 0.000 claims 1
- NZNSESWVOLCQQL-UHFFFAOYSA-N 4-n-(2-naphthalen-2-ylcyclopropyl)cyclohexane-1,4-diamine Chemical compound C1CC(N)CCC1NC1C(C=2C=C3C=CC=CC3=CC=2)C1 NZNSESWVOLCQQL-UHFFFAOYSA-N 0.000 claims 1
- LMSFGWYBIGVSHX-JPPWEJMLSA-N 4-n-[(1r,2r)-2-(1,3-thiazol-5-yl)cyclopropyl]cyclohexane-1,4-diamine Chemical compound C1CC(N)CCC1N[C@H]1[C@H](C=2SC=NC=2)C1 LMSFGWYBIGVSHX-JPPWEJMLSA-N 0.000 claims 1
- WGTSRMDFUQLHJX-NEXFUWMNSA-N 4-n-[(1r,2r)-2-fluoro-2-phenylcyclopropyl]cyclohexane-1,4-diamine Chemical compound C1CC(N)CCC1N[C@H]1[C@@](C=2C=CC=CC=2)(F)C1 WGTSRMDFUQLHJX-NEXFUWMNSA-N 0.000 claims 1
- ALHBJBCQLJZYON-NEXFUWMNSA-N 4-n-[(1r,2r)-2-phenylcyclopropyl]cyclohexane-1,4-diamine Chemical compound C1CC(N)CCC1N[C@H]1[C@@H](C=2C=CC=CC=2)C1 ALHBJBCQLJZYON-NEXFUWMNSA-N 0.000 claims 1
- XYAZRGFFUVDRRE-JTEKXYAQSA-N 4-n-[(1r,2s)-2-(2-fluorophenyl)cyclopropyl]cyclohexane-1,4-diamine Chemical compound C1CC(N)CCC1N[C@H]1[C@H](C=2C(=CC=CC=2)F)C1 XYAZRGFFUVDRRE-JTEKXYAQSA-N 0.000 claims 1
- VUUUJQSTZWEXHY-FPCDFSMTSA-N 4-n-[(1r,2s)-2-(2-methylphenyl)cyclopropyl]cyclohexane-1,4-diamine Chemical compound CC1=CC=CC=C1[C@H]1[C@H](NC2CCC(N)CC2)C1 VUUUJQSTZWEXHY-FPCDFSMTSA-N 0.000 claims 1
- GADXVPHSTSJKLA-RJVJFLMVSA-N 4-n-[(1r,2s)-2-(3,4-difluorophenyl)cyclopropyl]cyclohexane-1,4-diamine Chemical compound C1CC(N)CCC1N[C@H]1[C@H](C=2C=C(F)C(F)=CC=2)C1 GADXVPHSTSJKLA-RJVJFLMVSA-N 0.000 claims 1
- ZCXOEWQARFTSEU-ZGUYJTEBSA-N 4-n-[(1r,2s)-2-(4-cyclopropylphenyl)cyclopropyl]cyclohexane-1,4-diamine Chemical compound C1CC(N)CCC1N[C@H]1[C@H](C=2C=CC(=CC=2)C2CC2)C1 ZCXOEWQARFTSEU-ZGUYJTEBSA-N 0.000 claims 1
- RETHRNCONJQITP-FPCDFSMTSA-N 4-n-[(1r,2s)-2-(4-methoxyphenyl)cyclopropyl]cyclohexane-1,4-diamine Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@H](NC2CCC(N)CC2)C1 RETHRNCONJQITP-FPCDFSMTSA-N 0.000 claims 1
- HPMSXSJJPUNVQO-IJZHQTRZSA-N 4-n-[(1r,2s)-2-(4-phenylmethoxyphenyl)cyclopropyl]cyclohexane-1,4-diamine Chemical compound C1CC(N)CCC1N[C@H]1[C@H](C=2C=CC(OCC=3C=CC=CC=3)=CC=2)C1 HPMSXSJJPUNVQO-IJZHQTRZSA-N 0.000 claims 1
- PJRFPYJEXUAIAO-GHBBCFCZSA-N 4-n-[(1r,2s)-2-(4-pyridin-3-ylphenyl)cyclopropyl]cyclohexane-1,4-diamine Chemical compound C1CC(N)CCC1N[C@H]1[C@H](C=2C=CC(=CC=2)C=2C=NC=CC=2)C1 PJRFPYJEXUAIAO-GHBBCFCZSA-N 0.000 claims 1
- YZUHPMZFIGGUPF-PEVXEQIPSA-N 4-n-[(1r,2s)-2-[4-(1h-indazol-6-yl)phenyl]cyclopropyl]cyclohexane-1,4-diamine Chemical compound C1CC(N)CCC1N[C@H]1[C@H](C=2C=CC(=CC=2)C=2C=C3NN=CC3=CC=2)C1 YZUHPMZFIGGUPF-PEVXEQIPSA-N 0.000 claims 1
- QMOFHXLCMXQBLM-UNGSAITNSA-N 4-n-[(1r,2s)-2-[4-(1h-pyrazol-5-yl)phenyl]cyclopropyl]cyclohexane-1,4-diamine Chemical compound C1CC(N)CCC1N[C@H]1[C@H](C=2C=CC(=CC=2)C=2NN=CC=2)C1 QMOFHXLCMXQBLM-UNGSAITNSA-N 0.000 claims 1
- KHBDVUZWCXIQKG-NSKBAKJYSA-N 4-n-[(1r,2s)-2-[4-(3-chlorophenyl)phenyl]cyclopropyl]cyclohexane-1,4-diamine Chemical compound C1CC(N)CCC1N[C@H]1[C@H](C=2C=CC(=CC=2)C=2C=C(Cl)C=CC=2)C1 KHBDVUZWCXIQKG-NSKBAKJYSA-N 0.000 claims 1
- LQYQJOCXYVTVDS-NSKBAKJYSA-N 4-n-[(1r,2s)-2-[4-(4-chlorophenyl)phenyl]cyclopropyl]cyclohexane-1,4-diamine Chemical compound C1CC(N)CCC1N[C@H]1[C@H](C=2C=CC(=CC=2)C=2C=CC(Cl)=CC=2)C1 LQYQJOCXYVTVDS-NSKBAKJYSA-N 0.000 claims 1
- FUXLXWZVYUFWPI-RRIIRSAJSA-N 4-n-[(1r,2s)-2-[4-(pyridin-3-ylmethoxy)phenyl]cyclopropyl]cyclohexane-1,4-diamine Chemical compound C1CC(N)CCC1N[C@H]1[C@H](C=2C=CC(OCC=3C=NC=CC=3)=CC=2)C1 FUXLXWZVYUFWPI-RRIIRSAJSA-N 0.000 claims 1
- FVUKYUBBWHTHQT-PFSRBDOWSA-N 4-n-[(1r,2s)-2-[4-(trifluoromethyl)phenyl]cyclopropyl]cyclohexane-1,4-diamine Chemical compound C1CC(N)CCC1N[C@H]1[C@H](C=2C=CC(=CC=2)C(F)(F)F)C1 FVUKYUBBWHTHQT-PFSRBDOWSA-N 0.000 claims 1
- HGQXBRHZRCCGGT-KLXIGZAZSA-N 4-n-[(1r,2s)-2-[4-[(2-fluorophenyl)methoxy]phenyl]cyclopropyl]cyclohexane-1,4-diamine Chemical compound C1CC(N)CCC1N[C@H]1[C@H](C=2C=CC(OCC=3C(=CC=CC=3)F)=CC=2)C1 HGQXBRHZRCCGGT-KLXIGZAZSA-N 0.000 claims 1
- FNABONOHFWWUDI-IJZHQTRZSA-N 4-n-[(1r,2s)-2-[4-[(3-fluorophenyl)methoxy]phenyl]cyclopropyl]cyclohexane-1,4-diamine Chemical compound C1CC(N)CCC1N[C@H]1[C@H](C=2C=CC(OCC=3C=C(F)C=CC=3)=CC=2)C1 FNABONOHFWWUDI-IJZHQTRZSA-N 0.000 claims 1
- TVYIZPPTJYFBQU-BDBAHPOVSA-N 4-n-[(1r,2s)-2-[4-[(3-piperazin-1-ylphenyl)methoxy]phenyl]cyclopropyl]cyclohexane-1,4-diamine Chemical compound C1CC(N)CCC1N[C@H]1[C@H](C=2C=CC(OCC=3C=C(C=CC=3)N3CCNCC3)=CC=2)C1 TVYIZPPTJYFBQU-BDBAHPOVSA-N 0.000 claims 1
- FARAMTXDGMKDAQ-IJZHQTRZSA-N 4-n-[(1r,2s)-2-[4-[(4-fluorophenyl)methoxy]phenyl]cyclopropyl]cyclohexane-1,4-diamine Chemical compound C1CC(N)CCC1N[C@H]1[C@H](C=2C=CC(OCC=3C=CC(F)=CC=3)=CC=2)C1 FARAMTXDGMKDAQ-IJZHQTRZSA-N 0.000 claims 1
- YIHUNTSCCUBOJN-NSKBAKJYSA-N 4-n-[(1r,2s)-2-[6-[(3-methylphenyl)methylamino]pyridin-3-yl]cyclopropyl]cyclohexane-1,4-diamine Chemical compound CC1=CC=CC(CNC=2N=CC(=CC=2)[C@H]2[C@@H](C2)NC2CCC(N)CC2)=C1 YIHUNTSCCUBOJN-NSKBAKJYSA-N 0.000 claims 1
- GJVAQLSJDKEYGJ-QQGUTBHFSA-N 4-n-[(1r,2s)-2-[6-[3-(trifluoromethyl)phenyl]pyridin-3-yl]cyclopropyl]cyclohexane-1,4-diamine Chemical compound C1CC(N)CCC1N[C@H]1[C@H](C=2C=NC(=CC=2)C=2C=C(C=CC=2)C(F)(F)F)C1 GJVAQLSJDKEYGJ-QQGUTBHFSA-N 0.000 claims 1
- NZNSESWVOLCQQL-WZOJCFFYSA-N 4-n-[(1r,2s)-2-naphthalen-2-ylcyclopropyl]cyclohexane-1,4-diamine Chemical compound C1CC(N)CCC1N[C@H]1[C@H](C=2C=C3C=CC=CC3=CC=2)C1 NZNSESWVOLCQQL-WZOJCFFYSA-N 0.000 claims 1
- QAZSEXHFQQZAIT-CLRIEMFWSA-N 4-n-[(1r,2s)-2-pyridin-3-ylcyclopropyl]cyclohexane-1,4-diamine Chemical compound C1CC(N)CCC1N[C@H]1[C@H](C=2C=NC=CC=2)C1 QAZSEXHFQQZAIT-CLRIEMFWSA-N 0.000 claims 1
- BINXOHRETRQOCW-VFUGHAIPSA-N 4-n-[(1s,2r)-2-[4-[3-(trifluoromethyl)phenyl]phenyl]cyclopropyl]cyclohexane-1,4-diamine Chemical compound C1CC(N)CCC1N[C@@H]1[C@@H](C=2C=CC(=CC=2)C=2C=C(C=CC=2)C(F)(F)F)C1 BINXOHRETRQOCW-VFUGHAIPSA-N 0.000 claims 1
- WGTSRMDFUQLHJX-WUCCLRPBSA-N 4-n-[(1s,2s)-2-fluoro-2-phenylcyclopropyl]cyclohexane-1,4-diamine Chemical compound C1CC(N)CCC1N[C@@H]1[C@](C=2C=CC=CC=2)(F)C1 WGTSRMDFUQLHJX-WUCCLRPBSA-N 0.000 claims 1
- XYAZRGFFUVDRRE-UHFFFAOYSA-N 4-n-[2-(2-fluorophenyl)cyclopropyl]cyclohexane-1,4-diamine Chemical compound C1CC(N)CCC1NC1C(C=2C(=CC=CC=2)F)C1 XYAZRGFFUVDRRE-UHFFFAOYSA-N 0.000 claims 1
- VUUUJQSTZWEXHY-UHFFFAOYSA-N 4-n-[2-(2-methylphenyl)cyclopropyl]cyclohexane-1,4-diamine Chemical compound CC1=CC=CC=C1C1C(NC2CCC(N)CC2)C1 VUUUJQSTZWEXHY-UHFFFAOYSA-N 0.000 claims 1
- GADXVPHSTSJKLA-UHFFFAOYSA-N 4-n-[2-(3,4-difluorophenyl)cyclopropyl]cyclohexane-1,4-diamine Chemical compound C1CC(N)CCC1NC1C(C=2C=C(F)C(F)=CC=2)C1 GADXVPHSTSJKLA-UHFFFAOYSA-N 0.000 claims 1
- RETHRNCONJQITP-UHFFFAOYSA-N 4-n-[2-(4-methoxyphenyl)cyclopropyl]cyclohexane-1,4-diamine Chemical compound C1=CC(OC)=CC=C1C1C(NC2CCC(N)CC2)C1 RETHRNCONJQITP-UHFFFAOYSA-N 0.000 claims 1
- FVUKYUBBWHTHQT-UHFFFAOYSA-N 4-n-[2-[4-(trifluoromethyl)phenyl]cyclopropyl]cyclohexane-1,4-diamine Chemical compound C1CC(N)CCC1NC1C(C=2C=CC(=CC=2)C(F)(F)F)C1 FVUKYUBBWHTHQT-UHFFFAOYSA-N 0.000 claims 1
- HZDYKFBUGRBRMH-QQGUTBHFSA-N 5-[5-[(1s,2r)-2-[(4-aminocyclohexyl)amino]cyclopropyl]pyridin-2-yl]-2-methylphenol Chemical compound C1=C(O)C(C)=CC=C1C1=CC=C([C@H]2[C@@H](C2)NC2CCC(N)CC2)C=N1 HZDYKFBUGRBRMH-QQGUTBHFSA-N 0.000 claims 1
- GADXVPHSTSJKLA-BLTAXRJOSA-N C1C[C@@H](N)CC[C@@H]1N[C@@H]1[C@@H](C=2C=C(F)C(F)=CC=2)C1 Chemical compound C1C[C@@H](N)CC[C@@H]1N[C@@H]1[C@@H](C=2C=C(F)C(F)=CC=2)C1 GADXVPHSTSJKLA-BLTAXRJOSA-N 0.000 claims 1
- NZNSESWVOLCQQL-MKXGPGLRSA-N C1C[C@@H](N)CC[C@@H]1N[C@@H]1[C@@H](C=2C=C3C=CC=CC3=CC=2)C1 Chemical compound C1C[C@@H](N)CC[C@@H]1N[C@@H]1[C@@H](C=2C=C3C=CC=CC3=CC=2)C1 NZNSESWVOLCQQL-MKXGPGLRSA-N 0.000 claims 1
- BINXOHRETRQOCW-NCYKPQTJSA-N C1C[C@@H](N)CC[C@@H]1N[C@@H]1[C@@H](C=2C=CC(=CC=2)C=2C=C(C=CC=2)C(F)(F)F)C1 Chemical compound C1C[C@@H](N)CC[C@@H]1N[C@@H]1[C@@H](C=2C=CC(=CC=2)C=2C=C(C=CC=2)C(F)(F)F)C1 BINXOHRETRQOCW-NCYKPQTJSA-N 0.000 claims 1
- QMOFHXLCMXQBLM-KONPQCLYSA-N C1C[C@@H](N)CC[C@@H]1N[C@@H]1[C@@H](C=2C=CC(=CC=2)C=2NN=CC=2)C1 Chemical compound C1C[C@@H](N)CC[C@@H]1N[C@@H]1[C@@H](C=2C=CC(=CC=2)C=2NN=CC=2)C1 QMOFHXLCMXQBLM-KONPQCLYSA-N 0.000 claims 1
- HGQXBRHZRCCGGT-DBQGFPOUSA-N C1C[C@@H](N)CC[C@@H]1N[C@@H]1[C@@H](C=2C=CC(OCC=3C(=CC=CC=3)F)=CC=2)C1 Chemical compound C1C[C@@H](N)CC[C@@H]1N[C@@H]1[C@@H](C=2C=CC(OCC=3C(=CC=CC=3)F)=CC=2)C1 HGQXBRHZRCCGGT-DBQGFPOUSA-N 0.000 claims 1
- ALHBJBCQLJZYON-TUVASFSCSA-N C1C[C@@H](N)CC[C@@H]1N[C@@H]1[C@@H](C=2C=CC=CC=2)C1 Chemical compound C1C[C@@H](N)CC[C@@H]1N[C@@H]1[C@@H](C=2C=CC=CC=2)C1 ALHBJBCQLJZYON-TUVASFSCSA-N 0.000 claims 1
- QAZSEXHFQQZAIT-SYQHCUMBSA-N C1C[C@@H](N)CC[C@@H]1N[C@@H]1[C@@H](C=2C=NC=CC=2)C1 Chemical compound C1C[C@@H](N)CC[C@@H]1N[C@@H]1[C@@H](C=2C=NC=CC=2)C1 QAZSEXHFQQZAIT-SYQHCUMBSA-N 0.000 claims 1
- GADXVPHSTSJKLA-JUFZMCDQSA-N C1C[C@@H](N)CC[C@@H]1N[C@H]1[C@H](C=2C=C(F)C(F)=CC=2)C1 Chemical compound C1C[C@@H](N)CC[C@@H]1N[C@H]1[C@H](C=2C=C(F)C(F)=CC=2)C1 GADXVPHSTSJKLA-JUFZMCDQSA-N 0.000 claims 1
- NZNSESWVOLCQQL-CADBVGFASA-N C1C[C@@H](N)CC[C@@H]1N[C@H]1[C@H](C=2C=C3C=CC=CC3=CC=2)C1 Chemical compound C1C[C@@H](N)CC[C@@H]1N[C@H]1[C@H](C=2C=C3C=CC=CC3=CC=2)C1 NZNSESWVOLCQQL-CADBVGFASA-N 0.000 claims 1
- BINXOHRETRQOCW-XSDIEEQYSA-N C1C[C@@H](N)CC[C@@H]1N[C@H]1[C@H](C=2C=CC(=CC=2)C=2C=C(C=CC=2)C(F)(F)F)C1 Chemical compound C1C[C@@H](N)CC[C@@H]1N[C@H]1[C@H](C=2C=CC(=CC=2)C=2C=C(C=CC=2)C(F)(F)F)C1 BINXOHRETRQOCW-XSDIEEQYSA-N 0.000 claims 1
- QMOFHXLCMXQBLM-NBOOPKSLSA-N C1C[C@@H](N)CC[C@@H]1N[C@H]1[C@H](C=2C=CC(=CC=2)C=2NN=CC=2)C1 Chemical compound C1C[C@@H](N)CC[C@@H]1N[C@H]1[C@H](C=2C=CC(=CC=2)C=2NN=CC=2)C1 QMOFHXLCMXQBLM-NBOOPKSLSA-N 0.000 claims 1
- HGQXBRHZRCCGGT-RJOZEALSSA-N C1C[C@@H](N)CC[C@@H]1N[C@H]1[C@H](C=2C=CC(OCC=3C(=CC=CC=3)F)=CC=2)C1 Chemical compound C1C[C@@H](N)CC[C@@H]1N[C@H]1[C@H](C=2C=CC(OCC=3C(=CC=CC=3)F)=CC=2)C1 HGQXBRHZRCCGGT-RJOZEALSSA-N 0.000 claims 1
- GADXVPHSTSJKLA-ZAZJYDDPSA-N C1C[C@@H](N)CC[C@H]1N[C@@H]1[C@@H](C=2C=C(F)C(F)=CC=2)C1 Chemical compound C1C[C@@H](N)CC[C@H]1N[C@@H]1[C@@H](C=2C=C(F)C(F)=CC=2)C1 GADXVPHSTSJKLA-ZAZJYDDPSA-N 0.000 claims 1
- NZNSESWVOLCQQL-HCXYKTFWSA-N C1C[C@@H](N)CC[C@H]1N[C@@H]1[C@@H](C=2C=C3C=CC=CC3=CC=2)C1 Chemical compound C1C[C@@H](N)CC[C@H]1N[C@@H]1[C@@H](C=2C=C3C=CC=CC3=CC=2)C1 NZNSESWVOLCQQL-HCXYKTFWSA-N 0.000 claims 1
- QMOFHXLCMXQBLM-HPFXQQBRSA-N C1C[C@@H](N)CC[C@H]1N[C@@H]1[C@@H](C=2C=CC(=CC=2)C=2NN=CC=2)C1 Chemical compound C1C[C@@H](N)CC[C@H]1N[C@@H]1[C@@H](C=2C=CC(=CC=2)C=2NN=CC=2)C1 QMOFHXLCMXQBLM-HPFXQQBRSA-N 0.000 claims 1
- HGQXBRHZRCCGGT-MXKPZRPRSA-N C1C[C@@H](N)CC[C@H]1N[C@@H]1[C@@H](C=2C=CC(OCC=3C(=CC=CC=3)F)=CC=2)C1 Chemical compound C1C[C@@H](N)CC[C@H]1N[C@@H]1[C@@H](C=2C=CC(OCC=3C(=CC=CC=3)F)=CC=2)C1 HGQXBRHZRCCGGT-MXKPZRPRSA-N 0.000 claims 1
- ALHBJBCQLJZYON-BARDWOONSA-N C1C[C@@H](N)CC[C@H]1N[C@@H]1[C@@H](C=2C=CC=CC=2)C1 Chemical compound C1C[C@@H](N)CC[C@H]1N[C@@H]1[C@@H](C=2C=CC=CC=2)C1 ALHBJBCQLJZYON-BARDWOONSA-N 0.000 claims 1
- QAZSEXHFQQZAIT-RQJABVFESA-N C1C[C@@H](N)CC[C@H]1N[C@@H]1[C@@H](C=2C=NC=CC=2)C1 Chemical compound C1C[C@@H](N)CC[C@H]1N[C@@H]1[C@@H](C=2C=NC=CC=2)C1 QAZSEXHFQQZAIT-RQJABVFESA-N 0.000 claims 1
- GADXVPHSTSJKLA-OZTPJHRESA-N C1C[C@@H](N)CC[C@H]1N[C@H]1[C@H](C=2C=C(F)C(F)=CC=2)C1 Chemical compound C1C[C@@H](N)CC[C@H]1N[C@H]1[C@H](C=2C=C(F)C(F)=CC=2)C1 GADXVPHSTSJKLA-OZTPJHRESA-N 0.000 claims 1
- NZNSESWVOLCQQL-ZSYWTGECSA-N C1C[C@@H](N)CC[C@H]1N[C@H]1[C@H](C=2C=C3C=CC=CC3=CC=2)C1 Chemical compound C1C[C@@H](N)CC[C@H]1N[C@H]1[C@H](C=2C=C3C=CC=CC3=CC=2)C1 NZNSESWVOLCQQL-ZSYWTGECSA-N 0.000 claims 1
- QMOFHXLCMXQBLM-UIBIWLFHSA-N C1C[C@@H](N)CC[C@H]1N[C@H]1[C@H](C=2C=CC(=CC=2)C=2NN=CC=2)C1 Chemical compound C1C[C@@H](N)CC[C@H]1N[C@H]1[C@H](C=2C=CC(=CC=2)C=2NN=CC=2)C1 QMOFHXLCMXQBLM-UIBIWLFHSA-N 0.000 claims 1
- HGQXBRHZRCCGGT-GXKRZCMTSA-N C1C[C@@H](N)CC[C@H]1N[C@H]1[C@H](C=2C=CC(OCC=3C(=CC=CC=3)F)=CC=2)C1 Chemical compound C1C[C@@H](N)CC[C@H]1N[C@H]1[C@H](C=2C=CC(OCC=3C(=CC=CC=3)F)=CC=2)C1 HGQXBRHZRCCGGT-GXKRZCMTSA-N 0.000 claims 1
- ALHBJBCQLJZYON-LJISPDSOSA-N C1C[C@@H](N)CC[C@H]1N[C@H]1[C@H](C=2C=CC=CC=2)C1 Chemical compound C1C[C@@H](N)CC[C@H]1N[C@H]1[C@H](C=2C=CC=CC=2)C1 ALHBJBCQLJZYON-LJISPDSOSA-N 0.000 claims 1
- QAZSEXHFQQZAIT-RFQIPJPRSA-N C1C[C@@H](N)CC[C@H]1N[C@H]1[C@H](C=2C=NC=CC=2)C1 Chemical compound C1C[C@@H](N)CC[C@H]1N[C@H]1[C@H](C=2C=NC=CC=2)C1 QAZSEXHFQQZAIT-RFQIPJPRSA-N 0.000 claims 1
- MDWANQHRPJNECZ-LPWJVIDDSA-N C1[C@@H](N)C[C@@H]1N[C@@H]1[C@@H](C=2C=CC=CC=2)C1 Chemical compound C1[C@@H](N)C[C@@H]1N[C@@H]1[C@@H](C=2C=CC=CC=2)C1 MDWANQHRPJNECZ-LPWJVIDDSA-N 0.000 claims 1
- MDWANQHRPJNECZ-ZDEQEGDKSA-N C1[C@@H](N)C[C@@H]1N[C@H]1[C@H](C=2C=CC=CC=2)C1 Chemical compound C1[C@@H](N)C[C@@H]1N[C@H]1[C@H](C=2C=CC=CC=2)C1 MDWANQHRPJNECZ-ZDEQEGDKSA-N 0.000 claims 1
- MDWANQHRPJNECZ-XQHKEYJVSA-N C1[C@@H](N)C[C@H]1N[C@@H]1[C@@H](C=2C=CC=CC=2)C1 Chemical compound C1[C@@H](N)C[C@H]1N[C@@H]1[C@@H](C=2C=CC=CC=2)C1 MDWANQHRPJNECZ-XQHKEYJVSA-N 0.000 claims 1
- MDWANQHRPJNECZ-QNWHQSFQSA-N C1[C@@H](N)C[C@H]1N[C@H]1[C@H](C=2C=CC=CC=2)C1 Chemical compound C1[C@@H](N)C[C@H]1N[C@H]1[C@H](C=2C=CC=CC=2)C1 MDWANQHRPJNECZ-QNWHQSFQSA-N 0.000 claims 1
- IJWYHMIMXOCAJF-UHFFFAOYSA-N N-[3-[4-[2-[(4-aminocyclohexyl)amino]cyclopropyl]phenyl]-4-methoxyphenyl]methanesulfonamide Chemical compound COC1=CC=C(NS(C)(=O)=O)C=C1C1=CC=C(C2C(C2)NC2CCC(N)CC2)C=C1 IJWYHMIMXOCAJF-UHFFFAOYSA-N 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 239000003638 chemical reducing agent Substances 0.000 claims 1
- PNZXMIKHJXIPEK-UHFFFAOYSA-N cyclohexanecarboxamide Chemical compound NC(=O)C1CCCCC1 PNZXMIKHJXIPEK-UHFFFAOYSA-N 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 claims 1
- BHRMTBMFKWLVQR-UAQOYQIJSA-N n-[3-[4-[(1s,2r)-2-[(4-aminocyclohexyl)amino]cyclopropyl]phenyl]phenyl]-2-cyanobenzenesulfonamide Chemical compound C1CC(N)CCC1N[C@H]1[C@H](C=2C=CC(=CC=2)C=2C=C(NS(=O)(=O)C=3C(=CC=CC=3)C#N)C=CC=2)C1 BHRMTBMFKWLVQR-UAQOYQIJSA-N 0.000 claims 1
- YRKFSFINIZVZMR-IJZHQTRZSA-N n-[3-[4-[(1s,2r)-2-[(4-aminocyclohexyl)amino]cyclopropyl]phenyl]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC(C=2C=CC(=CC=2)[C@H]2[C@@H](C2)NC2CCC(N)CC2)=C1 YRKFSFINIZVZMR-IJZHQTRZSA-N 0.000 claims 1
- GVFVFSPQLVQDNV-UIIQDGRDSA-N n-[3-[4-[(1s,2r)-2-[(4-aminocyclohexyl)amino]cyclopropyl]phenyl]phenyl]piperazine-1-sulfonamide Chemical compound C1CC(N)CCC1N[C@H]1[C@H](C=2C=CC(=CC=2)C=2C=C(NS(=O)(=O)N3CCNCC3)C=CC=2)C1 GVFVFSPQLVQDNV-UIIQDGRDSA-N 0.000 claims 1
- YGALSGSYVHMATA-SLMMIHQXSA-N n-[3-[5-[(1r,2r)-2-[(4-aminocyclohexyl)amino]cyclopropyl]-1,3-thiazol-2-yl]phenyl]-2-cyanobenzenesulfonamide Chemical compound C1CC(N)CCC1N[C@H]1[C@H](C=2SC(=NC=2)C=2C=C(NS(=O)(=O)C=3C(=CC=CC=3)C#N)C=CC=2)C1 YGALSGSYVHMATA-SLMMIHQXSA-N 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11382324.9 | 2011-10-20 | ||
| EP11382324 | 2011-10-20 | ||
| EP11382329 | 2011-10-27 | ||
| EP11382329.8 | 2011-10-27 | ||
| US201161558369P | 2011-11-10 | 2011-11-10 | |
| US201161558370P | 2011-11-10 | 2011-11-10 | |
| US61/558,370 | 2011-11-10 | ||
| US61/558,369 | 2011-11-10 | ||
| PCT/EP2012/070900 WO2013057322A1 (en) | 2011-10-20 | 2012-10-22 | (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016222911A Division JP2017075155A (ja) | 2011-10-20 | 2016-11-16 | Ｌｓｄ１阻害剤としての（ヘテロ）アリールシクロプロピルアミン化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015502335A JP2015502335A (ja) | 2015-01-22 |
| JP2015502335A5 true JP2015502335A5 (cg-RX-API-DMAC7.html) | 2015-12-10 |
| JP6046154B2 JP6046154B2 (ja) | 2016-12-14 |
Family
ID=48140383
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014536287A Active JP6046154B2 (ja) | 2011-10-20 | 2012-10-22 | Ｌｓｄ１阻害剤としての（ヘテロ）アリールシクロプロピルアミン化合物 |
| JP2016222911A Withdrawn JP2017075155A (ja) | 2011-10-20 | 2016-11-16 | Ｌｓｄ１阻害剤としての（ヘテロ）アリールシクロプロピルアミン化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016222911A Withdrawn JP2017075155A (ja) | 2011-10-20 | 2016-11-16 | Ｌｓｄ１阻害剤としての（ヘテロ）アリールシクロプロピルアミン化合物 |
Country Status (25)
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8993808B2 (en) | 2009-01-21 | 2015-03-31 | Oryzon Genomics, S.A. | Phenylcyclopropylamine derivatives and their medical use |
| BR112012006572A2 (pt) | 2009-09-25 | 2016-04-26 | Oryzon Genomics Sa | inibidores de demetilase-1 de lisina específicos e seu uso |
| WO2011042217A1 (en) | 2009-10-09 | 2011-04-14 | Oryzon Genomics S.A. | Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use |
| US9616058B2 (en) | 2010-02-24 | 2017-04-11 | Oryzon Genomics, S.A. | Potent selective LSD1 inhibitors and dual LSD1/MAO-B inhibitors for antiviral use |
| WO2011106573A2 (en) | 2010-02-24 | 2011-09-01 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae |
| AU2011244325B2 (en) | 2010-04-19 | 2015-12-17 | Oryzon Genomics S.A. | Lysine specific demethylase-1 inhibitors and their use |
| WO2012013727A1 (en) | 2010-07-29 | 2012-02-02 | Oryzon Genomics S.A. | Cyclopropylamine derivatives useful as lsd1 inhibitors |
| CA2806008C (en) | 2010-07-29 | 2019-07-09 | Oryzon Genomics S.A. | Arylcyclopropylamine based demethylase inhibitors of lsd1 and their medical use |
| WO2012045883A1 (en) | 2010-10-08 | 2012-04-12 | Oryzon Genomics S.A. | Cyclopropylamine inhibitors of oxidases |
| WO2012072713A2 (en) | 2010-11-30 | 2012-06-07 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae |
| EP3981395A1 (en) | 2011-02-08 | 2022-04-13 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for myeloproliferative disorders |
| EP2768805B1 (en) | 2011-10-20 | 2020-03-25 | Oryzon Genomics, S.A. | (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors |
| KR102079406B1 (ko) * | 2011-10-20 | 2020-02-19 | 오리존 지노믹스 에스.에이. | Lsd1 억제제로서의 (헤테로)아릴 사이클로프로필아민 화합물 |
| EP2907802B1 (en) | 2012-10-12 | 2019-08-07 | Takeda Pharmaceutical Company Limited | Cyclopropanamine compound and use thereof |
| EP2740474A1 (en) | 2012-12-05 | 2014-06-11 | Instituto Europeo di Oncologia S.r.l. | Cyclopropylamine derivatives useful as inhibitors of histone demethylases kdm1a |
| BR112016002496B1 (pt) | 2013-08-06 | 2022-07-12 | Imago Biosciences Inc. | Composto e composição farmacêutica |
| CN106164066B (zh) | 2014-02-13 | 2020-01-17 | 因赛特公司 | 作为lsd1抑制剂的环丙胺 |
| US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| JP6602779B2 (ja) * | 2014-02-13 | 2019-11-06 | インサイト・コーポレイション | Ｌｓｄ１阻害剤としてのシクロプロピルアミン類 |
| US9493442B2 (en) | 2014-02-13 | 2016-11-15 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| UY36071A (es) | 2014-04-11 | 2015-11-30 | Takeda Pharmaceutical | Compuesto de ciclopropanamina y sus usos |
| WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| TW201613925A (en) | 2014-07-10 | 2016-04-16 | Incyte Corp | Imidazopyrazines as LSD1 inhibitors |
| WO2016007727A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| US9695168B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors |
| ES2973286T3 (es) * | 2014-11-26 | 2024-06-19 | St Europeo Di Oncologia S R L | Modelos de trastornos del desarrollo neurológico basados en la reprogramación y usos de los mismos |
| ES3005884T3 (en) | 2015-02-12 | 2025-03-17 | Imago Biosciences Inc | A kdm1a inhibitor and its use in therapy |
| CN107660205B (zh) | 2015-04-03 | 2021-08-27 | 因赛特公司 | 作为lsd1抑制剂的杂环化合物 |
| EP3090998A1 (en) * | 2015-05-06 | 2016-11-09 | F. Hoffmann-La Roche AG | Solid forms |
| US20180284095A1 (en) | 2015-06-12 | 2018-10-04 | Oryzon Genomics, S.A. | Biomarkers associated with lsd1 inhibitors and uses thereof |
| WO2017013061A1 (en) | 2015-07-17 | 2017-01-26 | Oryzon Genomics, S.A. | Biomarkers associated with lsd1 inhibitors and uses thereof |
| EA035534B1 (ru) | 2015-08-12 | 2020-06-30 | Инсайт Корпорейшн | Соли ингибитора lsd1 |
| US10059668B2 (en) | 2015-11-05 | 2018-08-28 | Mirati Therapeutics, Inc. | LSD1 inhibitors |
| SG11201805645QA (en) | 2015-12-29 | 2018-07-30 | Mirati Therapeutics Inc | Lsd1 inhibitors |
| EP4219689A3 (en) | 2015-12-30 | 2023-12-20 | Novartis AG | Immune effector cell therapies with enhanced efficacy |
| CN107174584B (zh) * | 2016-03-12 | 2020-09-01 | 福建金乐医药科技有限公司 | 含哌嗪结构化合物在制备lsd1抑制剂中的应用 |
| CA3017411C (en) * | 2016-03-15 | 2024-06-25 | Oryzon Genomics, S.A. | Combinations of lsd1 inhibitors for use in the treatment of solid tumors |
| CA3253937A1 (en) | 2016-03-15 | 2025-03-04 | Oryzon Genomics, S.A. | Combinations of Lysine-Specific Demethylase 1 Inhibitors for the Treatment of Hematological Maligna |
| CN107200706A (zh) * | 2016-03-16 | 2017-09-26 | 中国科学院上海药物研究所 | 一类氟取代的环丙胺类化合物及其制备方法、药物组合物和用途 |
| EP3430015B9 (en) | 2016-03-16 | 2025-12-31 | Oryzon Genomics, S.A. | METHODS FOR DETERMINING THE ENGAGEMENT OF A KDM1A TARGET AND CORRESPONDING USEFUL CHEMOPROBE |
| BR112018071585B1 (pt) | 2016-04-22 | 2024-01-02 | Incyte Corporation | Formulações de um inibidor de lsd1, seus usos e método de preparação das mesmas |
| ES2732669T3 (es) | 2016-06-10 | 2019-11-25 | Oryzon Genomics Sa | Tratamiento de la esclerosis múltiple |
| WO2018035259A1 (en) | 2016-08-16 | 2018-02-22 | Imago Biosciences, Inc. | Methods and processes for the preparation of kdm1a inhibitors |
| WO2018083138A1 (en) | 2016-11-03 | 2018-05-11 | Oryzon Genomics, S.A. | Pharmacodynamic biomarkers for personalized cancer care using epigenetic modifying agents |
| US20190256930A1 (en) | 2016-11-03 | 2019-08-22 | Oryzon Genomics, S.A. | Biomarkers for determining responsiveness to lsd1 inhibitors |
| WO2018197583A1 (en) | 2017-04-26 | 2018-11-01 | Istituto Europeo Di Oncologia | Use of a combinational therapy of lsd1 inhibitors with p21 activators in the treatment of cancer |
| JP2020152641A (ja) * | 2017-07-07 | 2020-09-24 | 国立研究開発法人理化学研究所 | リジン特異的脱メチル化酵素１阻害活性を有する新規化合物、その製造方法及びその用途 |
| AU2018309372B2 (en) | 2017-08-03 | 2024-08-15 | Oryzon Genomics, S.A. | Methods of treating behavior alterations |
| WO2019068326A1 (en) | 2017-10-05 | 2019-04-11 | Université D'aix-Marseille | INHIBITORS OF LSD1 FOR THE TREATMENT AND PREVENTION OF CARDIOMYOPATHIES |
| CN112040934A (zh) | 2018-05-04 | 2020-12-04 | 奥莱松基因组股份有限公司 | 稳定的药物制剂 |
| AU2019265022B2 (en) | 2018-05-11 | 2024-08-15 | Imago Biosciences, Inc. | KDM1A inhibitors for the treatment of disease |
| US10968200B2 (en) | 2018-08-31 | 2021-04-06 | Incyte Corporation | Salts of an LSD1 inhibitor and processes for preparing the same |
| AU2020242302B2 (en) | 2019-03-20 | 2025-10-30 | Oryzon Genomics, S.A. | Methods of treating borderline personality disorder |
| CN113631164A (zh) | 2019-03-20 | 2021-11-09 | 奥莱松基因组股份有限公司 | 使用kdm1a抑制剂如化合物伐菲德司他治疗注意缺陷多动症的方法 |
| WO2020193631A1 (en) | 2019-03-25 | 2020-10-01 | Oryzon Genomics, S.A. | Combinations of iadademstat for cancer therapy |
| JP2022546908A (ja) | 2019-07-05 | 2022-11-10 | オリゾン・ゲノミクス・ソシエダッド・アノニマ | Ｋｄｍ１ａ阻害剤を使用した小細胞肺がんの個別化された処置のためのバイオマーカーおよび方法 |
| IT202000007873A1 (it) | 2020-04-14 | 2021-10-14 | St Europeo Di Oncologia S R L | Molecole per uso nel trattamento delle infezioni virali |
| WO2022011458A1 (en) * | 2020-07-13 | 2022-01-20 | Ontario Institute For Cancer Research (Oicr) | Nicotinamide phosphoribosyltransferase (nampt) inhibitor-conjugates and uses thereof |
| EP3964204A1 (en) | 2020-09-08 | 2022-03-09 | Université d'Aix-Marseille | Lsd1 inhibitors for use in the treatment and prevention of fibrosis of tissues |
| AU2022254484A1 (en) | 2021-04-08 | 2023-11-09 | Oryzon Genomics, S.A. | Combinations of lsd1 inhibitors for treating myeloid cancers |
| WO2022221493A1 (en) | 2021-04-14 | 2022-10-20 | Neuropn Therapeutics, Llc | Piperidine urea derivatives as soluble epoxide hydrolase inhibitors |
| JP2025516648A (ja) | 2022-05-09 | 2025-05-30 | オリゾン・ゲノミクス・ソシエダッド・アノニマ | Ｌｓｄ１阻害薬を用いるｎｆ１変異腫瘍の治療法 |
| WO2023217758A1 (en) | 2022-05-09 | 2023-11-16 | Oryzon Genomics, S.A. | Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors |
| US20240139172A1 (en) | 2022-09-30 | 2024-05-02 | NeuroPn Therapeutics, Inc. | Piperidine urea derivatives for cancer therapy |
| CN120225192A (zh) | 2022-09-30 | 2025-06-27 | 纽若平治疗公司 | 用于治疗神经退行性疾病的哌啶脲衍生物 |
| KR20250109775A (ko) | 2022-11-24 | 2025-07-17 | 오리존 지노믹스 에스.에이. | 암 치료를 위한 lsd1 억제제 및 메닌 억제제의 조합 |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
| GB202400822D0 (en) | 2024-01-22 | 2024-03-06 | Imperagen Ltd | Manufacture of LSD1 inhibitor |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (130)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3106578A (en) | 1960-09-16 | 1963-10-08 | Smith Kline French Lab | Nu-phenethyl-2-phenylcyclopropylamine derivatives |
| US3365458A (en) | 1964-06-23 | 1968-01-23 | Aldrich Chem Co Inc | N-aryl-n'-cyclopropyl-ethylene diamine derivatives |
| US3532749A (en) | 1965-05-11 | 1970-10-06 | Aldrich Chem Co Inc | N'-propargyl-n**2-cyclopropyl-ethylenediamines and the salts thereof |
| US3471522A (en) | 1967-09-29 | 1969-10-07 | Aldrich Chem Co Inc | N-cyclopropyl-n'-furfuryl-n'-methyl ethylene diamines |
| US3532712A (en) | 1967-09-29 | 1970-10-06 | Aldrich Chem Co Inc | N'-cyclopropyl ethylenediamine derivatives |
| US3654306A (en) | 1970-01-26 | 1972-04-04 | Robins Co Inc A H | 5-azaspiro(2.4)heptane-4 6-diones |
| US3758684A (en) | 1971-09-07 | 1973-09-11 | Burroughs Wellcome Co | Treating dna virus infections with amino purine derivatives |
| US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
| US4409243A (en) | 1981-11-09 | 1983-10-11 | Julian Lieb | Treatment of auto-immune and inflammatory diseases |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| GB9311282D0 (en) | 1993-06-01 | 1993-07-21 | Rhone Poulenc Rorer Ltd | New compositions of matter |
| EP1275635A1 (en) | 1994-10-21 | 2003-01-15 | Nps Pharmaceuticals, Inc. | Calcium receptor-active compounds |
| US5652258A (en) | 1995-05-30 | 1997-07-29 | Gliatech, Inc. | 2-(4-imidazoyl) cyclopropyl derivatives |
| US20040132820A1 (en) | 1996-02-15 | 2004-07-08 | Jean Gosselin | Agents with leukotriene B4-like antiviral (DNA) and anti-neoplastic activities |
| GB9615730D0 (en) | 1996-07-26 | 1996-09-04 | Medical Res Council | Anti-viral agent 1 |
| US5961987A (en) | 1996-10-31 | 1999-10-05 | University Of Iowa Research Foundation | Ocular protein stimulants |
| DE19647615A1 (de) | 1996-11-18 | 1998-05-20 | Bayer Ag | Verfahren zur Herstellung von Cyclopropylaminen |
| TW530058B (en) | 1997-07-22 | 2003-05-01 | Astra Pharma Prod | Triazolo [4,5-d]pyrimidine compounos and their use and process for preparation |
| SE9702772D0 (sv) | 1997-07-22 | 1997-07-22 | Astra Pharma Prod | Novel compounds |
| AU1631699A (en) | 1997-12-18 | 1999-07-05 | E.I. Du Pont De Nemours And Company | Cyclohexylamine arthropodicides and fungicides |
| US6809120B1 (en) | 1998-01-13 | 2004-10-26 | University Of Saskatchewan Technologies Inc. | Composition containing propargylamine for enhancing cancer therapy |
| DE69909459T2 (de) | 1998-04-21 | 2004-05-27 | Micromet Ag | Cd19xcd3 spezifische polypeptide und deren verwendung |
| SE9802206D0 (sv) | 1998-06-22 | 1998-06-22 | Astra Pharma Inc | Novel compounds |
| TWI229674B (en) | 1998-12-04 | 2005-03-21 | Astra Pharma Prod | Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses |
| US7321050B2 (en) | 1999-12-06 | 2008-01-22 | Welichem Biotech Inc. | Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues |
| PE20020062A1 (es) | 2000-05-26 | 2002-02-02 | Schering Corp | 5-AMINO-PIRAZOLO-[4,3-e]-1,2,4-TRIAZOLO[1,5-c]PIRIMIDINA COMO ANTAGONISTAS RECEPTORES DE ADENOSINA A2a |
| JP2001354563A (ja) | 2000-06-09 | 2001-12-25 | Sankyo Co Ltd | 置換ベンジルアミン類を含有する医薬 |
| US8519005B2 (en) | 2000-07-27 | 2013-08-27 | Thomas N. Thomas | Compositions and methods to prevent toxicity of antiinflammatory agents and enhance their efficacy |
| EP1193268A1 (en) | 2000-09-27 | 2002-04-03 | Applied Research Systems ARS Holding N.V. | Pharmaceutically active sulfonamide derivatives bearing both lipophilic and ionisable moieties as inhibitors of protein Junkinases |
| SK12012003A3 (en) | 2001-03-29 | 2004-10-05 | Bristol Myers Squibb Co | Cyclopropylindole derivatives as selective serotonin reuptake inhibitors |
| DE10123163A1 (de) | 2001-05-09 | 2003-01-16 | Gruenenthal Gmbh | Substituierte Cyclohexan-1,4-diaminderivate |
| US20030008844A1 (en) | 2001-05-17 | 2003-01-09 | Keryx Biopharmaceuticals, Inc. | Use of sulodexide for the treatment of inflammatory bowel disease |
| AU2003222786A1 (en) | 2002-04-18 | 2003-10-27 | Ucb, S.A. | Chemical compounds with dual activity, processes for their preparation and pharmaceutical compositions |
| EP1501514B1 (en) | 2002-05-03 | 2012-12-19 | Exelixis, Inc. | Protein kinase modulators and methods of use |
| US7704995B2 (en) | 2002-05-03 | 2010-04-27 | Exelixis, Inc. | Protein kinase modulators and methods of use |
| US7312214B2 (en) | 2002-05-10 | 2007-12-25 | Bristol-Myers Squibb Company | 1, 1-disubstituted cycloalkyl derivatives as factor Xa inhibitors |
| US7456222B2 (en) | 2002-05-17 | 2008-11-25 | Sequella, Inc. | Anti tubercular drug: compositions and methods |
| US6951961B2 (en) | 2002-05-17 | 2005-10-04 | Marina Nikolaevna Protopopova | Methods of use and compositions for the diagnosis and treatment of infectious disease |
| US20040033986A1 (en) | 2002-05-17 | 2004-02-19 | Protopopova Marina Nikolaevna | Anti tubercular drug: compositions and methods |
| PL215228B1 (pl) | 2002-05-20 | 2013-11-29 | Bristol Myers Squibb Co | Zwiazki tripeptydowe, ich zastosowanie i kompozycja farmaceutyczna je zawierajaca oraz jej zastosowanie |
| US7611704B2 (en) | 2002-07-15 | 2009-11-03 | Board Of Regents, The University Of Texas System | Compositions and methods for treating viral infections using antibodies and immunoconjugates to aminophospholipids |
| SE0202539D0 (sv) | 2002-08-27 | 2002-08-27 | Astrazeneca Ab | Compounds |
| AU2003296993A1 (en) | 2002-12-13 | 2004-07-09 | Smithkline Beecham Corporation | Cyclopropyl compounds as ccr5 antagonists |
| SG2012000667A (en) | 2003-01-08 | 2015-03-30 | Univ Washington | Antibacterial agents |
| US7223785B2 (en) | 2003-01-22 | 2007-05-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| GB0303439D0 (en) | 2003-02-14 | 2003-03-19 | Pfizer Ltd | Antiparasitic terpene alkaloids |
| US7186832B2 (en) | 2003-02-20 | 2007-03-06 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
| US7135575B2 (en) | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| DE602004023838D1 (de) | 2003-04-24 | 2009-12-10 | Merck & Co Inc | Hemmer der akt aktivität |
| EP1644320B1 (en) | 2003-07-03 | 2008-01-16 | Eli Lilly And Company | Indane derivates as muscarinic receptor agonists |
| JP4895811B2 (ja) | 2003-09-11 | 2012-03-14 | ケミア，インコーポレイテッド | サイトカイン阻害剤 |
| ES2385219T3 (es) | 2003-09-12 | 2012-07-19 | Merck Serono Sa | Derivados de sulfonamida para el tratamiento de diabetes |
| CN1897950A (zh) | 2003-10-14 | 2007-01-17 | 惠氏公司 | 稠合芳基和杂芳基衍生物及其使用方法 |
| EP1677799A4 (en) | 2003-10-21 | 2008-09-10 | Merck & Co Inc | TRIAZOLO-PYRIDAZINE COMPOUNDS AND DERIVATIVES THEREOF FOR THE TREATMENT OF NEUROPATHIC PAIN |
| US7026339B2 (en) | 2003-11-07 | 2006-04-11 | Fan Yang | Inhibitors of HCV NS5B polymerase |
| EP1694410B1 (en) | 2003-12-15 | 2010-04-14 | Japan Tobacco, Inc. | Cyclopropane derivatives and pharmaceutical use thereof |
| ZA200605247B (en) | 2003-12-15 | 2007-10-31 | Japan Tobacco Inc | N-substituted-n-sulfonylaminocyclopropane compounds and pharmaceutical use thereof |
| WO2005058883A1 (en) | 2003-12-15 | 2005-06-30 | Almirall Prodesfarma Ag | 2, 6 bisheteroaryl-4-aminopyrimidines as adenosine receptor antagonists |
| US7399825B2 (en) | 2003-12-24 | 2008-07-15 | Lipps Binie V | Synthetic peptide, inhibitor to DNA viruses |
| MXPA06012449A (es) | 2004-04-26 | 2007-01-17 | Pfizer | Inhibidores de la enzima integrasa de vih. |
| US20090275099A1 (en) | 2004-04-27 | 2009-11-05 | Regents Of The University Of Michigan | Methods and compositions for treating diseases and conditions associated with mitochondrial function |
| DE102004057594A1 (de) | 2004-11-29 | 2006-06-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Substitueirte Pteridine zur Behandlung von entzündlichen Erkrankungen |
| CA2591717A1 (en) | 2004-12-16 | 2006-07-06 | President And Fellows Of Harvard College | Histone demethylation mediated by the nuclear amine oxidase homolog lsd1 |
| DE602005022826D1 (de) | 2005-02-18 | 2010-09-23 | Universitaetsklinikum Freiburg | Kontrolle der Androgen Rezeptor-abhängigen Gen Expression durch Hemmung der Aminoxidase Aktivität der Lysin spezifischen Demethylase (LSD1) |
| US20060275366A1 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Controlled-release formulation |
| US7273882B2 (en) | 2005-06-21 | 2007-09-25 | Bristol-Myers Squibb Company | Aminoacetamide acyl guanidines as β-secretase inhibitors |
| EP1741708A1 (en) | 2005-06-28 | 2007-01-10 | Sanofi-Aventis Deutschland GmbH | Heteroaryl-substituted amides comprising an unsaturated or cyclic linker group, and their use as pharmaceuticals |
| EP2305697A3 (en) | 2005-07-25 | 2011-07-27 | Intermune, Inc. | Macrocyclic inhibitors of Hepatitis C virus replication |
| JP5484728B2 (ja) | 2005-08-10 | 2014-05-07 | ジョンズ ホプキンス ユニバーシティ | 抗寄生虫治療薬および抗癌治療薬ならびにリジン特異的デメチラーゼ阻害物質として有用なポリアミン類 |
| WO2007025144A1 (en) | 2005-08-24 | 2007-03-01 | University Of Illinois - Chicago | 5-ht2c receptor agonists as anorectic agents |
| GB0517740D0 (en) | 2005-08-31 | 2005-10-12 | Novartis Ag | Organic compounds |
| BRPI0617673C1 (pt) * | 2005-10-19 | 2012-05-22 | Ranbaxy Lab Ltd | composições de inibidores de fosfodiesterase do tipo iv |
| TW200745067A (en) | 2006-03-14 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
| US8618023B2 (en) | 2006-05-18 | 2013-12-31 | Syngenta Crop Protection, Llc | Microbiocides |
| US8198301B2 (en) | 2006-07-05 | 2012-06-12 | Hesheng Zhang | Quinazoline and quinoline derivatives as irreversibe protein tyrosine kinase inhibitors |
| EP2521786B1 (en) | 2006-07-20 | 2015-06-24 | Vical Incorporated | Compositions for vaccinating against hsv-2 |
| US20080161324A1 (en) | 2006-09-14 | 2008-07-03 | Johansen Lisa M | Compositions and methods for treatment of viral diseases |
| DE102007010801A1 (de) * | 2007-03-02 | 2008-09-04 | Bayer Cropscience Ag | Diaminopyrimidine als Fungizide |
| JP2010523685A (ja) | 2007-04-13 | 2010-07-15 | ザ・ジョンズ・ホプキンス・ユニバーシティー | リジン特異的デメチラーゼ阻害剤 |
| US7906513B2 (en) | 2007-04-26 | 2011-03-15 | Enanta Pharmaceuticals, Inc. | Hydrazide-containing hepatitis C serine protease inhibitors |
| HRP20141174T1 (hr) | 2007-06-27 | 2015-02-13 | Astrazeneca Ab | Derivati pirazinona i njihova uporaba za lijeäśenje bolesti pluä†a |
| CN101842098A (zh) | 2007-08-10 | 2010-09-22 | 基因实验室技术有限公司 | 用于治疗病毒感染的含氮的二环化学实体 |
| PT2203431E (pt) | 2007-09-17 | 2011-10-12 | Abbott Lab | Pirimidinas anti-infecciosas e seus usos |
| US20100016262A1 (en) | 2007-10-18 | 2010-01-21 | Yale University | Compositions and methods for reducing hepatotoxicity associated with drug administration and treating non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and associated cirrhosis |
| CA2702469A1 (en) | 2007-10-19 | 2009-04-23 | Boehringer Ingelheim International Gmbh | Ccr10 antagonists |
| CA2710417A1 (en) | 2007-12-26 | 2009-07-02 | Shionogi & Co., Ltd. | Glycosylated glycopeptide antibiotic derivatives |
| WO2009109991A2 (en) | 2008-01-23 | 2009-09-11 | Sun Pharma Advanced Research Company Ltd., | Novel hydrazide containing tyrosine kinase inhibitors |
| RU2497821C2 (ru) | 2008-01-28 | 2013-11-10 | Янссен Фармацевтика Нв | ПРОИЗВОДНЫЕ 6-ЗАМЕЩЕННОГО-ТИО (ИЛИ -ОКСО-)-2-АМИНО-ХИНОЛИНА, ПРИМЕНЯЕМЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ β-СЕКРЕТАЗЫ (BACE) |
| KR101922949B1 (ko) | 2008-03-19 | 2018-11-28 | 오림드 파마, 인코포레이티드 | 중추신경계 질환 및 질병 치료에 유효한 신규 화합물 |
| PE20121313A1 (es) | 2008-03-27 | 2012-10-07 | Gruenenthal Chemie | Derivados de 4-aminociclohexano sustituidos |
| CA2960692C (en) | 2008-04-16 | 2019-09-24 | Portola Pharmaceuticals, Inc. | 2,6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinase inhibitors |
| EP2303889A1 (en) | 2008-06-18 | 2011-04-06 | F. Hoffmann-La Roche AG | Halo-substituted pyrimidodiazepines as plkl inhibitors |
| EP2317992A2 (en) | 2008-07-24 | 2011-05-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Preventing or treating viral infection using an inhibitor of the lsd1 protein, a mao inhibitor or an inhibitor of lsd1 and a mao inhibitor |
| EP2331542B1 (en) | 2008-08-01 | 2016-07-27 | The United States of America, as Represented by The Secretary, Department of Health and Human Services | A3 adenosine receptor antagonists and partial agonists |
| US8048887B2 (en) | 2008-09-11 | 2011-11-01 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| WO2010043721A1 (en) | 2008-10-17 | 2010-04-22 | Oryzon Genomics, S.A. | Oxidase inhibitors and their use |
| US8993808B2 (en) | 2009-01-21 | 2015-03-31 | Oryzon Genomics, S.A. | Phenylcyclopropylamine derivatives and their medical use |
| WO2010085749A2 (en) | 2009-01-23 | 2010-07-29 | Northwestern University | Potent and selective neuronal nitric oxide synthase inhibitors with improved membrane permeability |
| EP2400846B1 (en) | 2009-02-27 | 2016-10-05 | Enanta Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
| ES2459468T3 (es) | 2009-05-15 | 2014-05-09 | Novartis Ag | Arilpiridinas como inhibidores de aldosterona sintasa |
| US8389580B2 (en) | 2009-06-02 | 2013-03-05 | Duke University | Arylcyclopropylamines and methods of use |
| EP2258865A1 (en) | 2009-06-05 | 2010-12-08 | Universitätsklinikum Freiburg | Lysine-specific demethylase 1 (LSD1) is a biomarker for breast cancer |
| JPWO2010143582A1 (ja) | 2009-06-11 | 2012-11-22 | 公立大学法人名古屋市立大学 | フェニルシクロプロピルアミン誘導体及びｌｓｄ１阻害剤 |
| EP2467359A4 (en) | 2009-08-18 | 2013-01-09 | Univ Johns Hopkins | (BIS-) UREA- AND (BIS-) THIOMINE COMPOUNDS AS EPIGENE MODULATORS OF THE LYSINE-SPECIFIC DEMETHYLASE 1 AND METHODS OF DISEASE TREATMENT THEREWITH |
| US20110045222A1 (en) | 2009-08-19 | 2011-02-24 | Eastman Chemical Company | Oxygen-scavenging polymer blends suitable for use in packaging |
| EP2475254A4 (en) | 2009-09-11 | 2013-05-22 | Enanta Pharm Inc | HEPATITIS C-VIRUS HEMMER |
| BR112012006572A2 (pt) | 2009-09-25 | 2016-04-26 | Oryzon Genomics Sa | inibidores de demetilase-1 de lisina específicos e seu uso |
| WO2011042217A1 (en) | 2009-10-09 | 2011-04-14 | Oryzon Genomics S.A. | Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use |
| WO2011057262A2 (en) | 2009-11-09 | 2011-05-12 | Evolva Inc. | Treatment of infections with tp receptor antagonists |
| WO2011106573A2 (en) | 2010-02-24 | 2011-09-01 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae |
| US9616058B2 (en) | 2010-02-24 | 2017-04-11 | Oryzon Genomics, S.A. | Potent selective LSD1 inhibitors and dual LSD1/MAO-B inhibitors for antiviral use |
| WO2011113005A2 (en) | 2010-03-12 | 2011-09-15 | The Johns Hopkins University | Compositions and methods for combinations of oligoamines with 2-difluoromethylornithine (dfmo) |
| AU2011244325B2 (en) | 2010-04-19 | 2015-12-17 | Oryzon Genomics S.A. | Lysine specific demethylase-1 inhibitors and their use |
| PL2560949T3 (pl) | 2010-04-20 | 2017-01-31 | Università Degli Studi Di Roma "La Sapienza" | Pochodne tranylocyprominy jako inhibitory demetylazy histonowej LSD1 i/lub LSD2 |
| EP2560939A2 (en) | 2010-04-20 | 2013-02-27 | Actavis Group Ptc Ehf | Novel process for preparing phenylcyclopropylamine derivatives using novel intermediates |
| EP2588441A2 (en) | 2010-06-30 | 2013-05-08 | Actavis Group Ptc Ehf | Novel processes for the preparation of phenylcyclopropylamine derivatives and use thereof for preparing ticagrelor |
| WO2012013727A1 (en) | 2010-07-29 | 2012-02-02 | Oryzon Genomics S.A. | Cyclopropylamine derivatives useful as lsd1 inhibitors |
| CA2806008C (en) | 2010-07-29 | 2019-07-09 | Oryzon Genomics S.A. | Arylcyclopropylamine based demethylase inhibitors of lsd1 and their medical use |
| US9527805B2 (en) | 2010-09-10 | 2016-12-27 | Robert A. Casero | Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders |
| US20130303545A1 (en) | 2010-09-30 | 2013-11-14 | Tamara Maes | Cyclopropylamine derivatives useful as lsd1 inhibitors |
| WO2012045883A1 (en) | 2010-10-08 | 2012-04-12 | Oryzon Genomics S.A. | Cyclopropylamine inhibitors of oxidases |
| WO2012072713A2 (en) | 2010-11-30 | 2012-06-07 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae |
| EP3981395A1 (en) | 2011-02-08 | 2022-04-13 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for myeloproliferative disorders |
| WO2012107499A1 (en) | 2011-02-08 | 2012-08-16 | Oryzon Genomics S.A. | Lysine demethylase inhibitors for myeloproliferative or lymphoproliferative diseases or disorders |
| KR101884493B1 (ko) * | 2011-03-25 | 2018-08-01 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | Lsd1 억제제로서의 시클로프로필아민 |
| US20140296255A1 (en) | 2011-05-19 | 2014-10-02 | Oryzong Genomics, S.A. | Lysine demethylase inhibitors for thrombosis and cardiovascular diseases |
| WO2012156531A2 (en) | 2011-05-19 | 2012-11-22 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for inflammatory diseases or conditions |
| MX2014001568A (es) * | 2011-08-09 | 2014-03-31 | Takeda Pharmaceutical | Compuesto de ciclopropanoamina. |
| EP2768805B1 (en) | 2011-10-20 | 2020-03-25 | Oryzon Genomics, S.A. | (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors |
| KR102079406B1 (ko) * | 2011-10-20 | 2020-02-19 | 오리존 지노믹스 에스.에이. | Lsd1 억제제로서의 (헤테로)아릴 사이클로프로필아민 화합물 |
-
2012
- 2012-10-22 KR KR1020147013558A patent/KR102079406B1/ko active Active
- 2012-10-22 PL PL12787388T patent/PL2776394T3/pl unknown
- 2012-10-22 RS RS20190282A patent/RS58475B1/sr unknown
- 2012-10-22 PE PE2014000548A patent/PE20141692A1/es active IP Right Grant
- 2012-10-22 PH PH1/2014/500860A patent/PH12014500860A1/en unknown
- 2012-10-22 SI SI201231552T patent/SI2776394T1/sl unknown
- 2012-10-22 MX MX2014004588A patent/MX351890B/es active IP Right Grant
- 2012-10-22 UA UAA201405198A patent/UA116765C2/uk unknown
- 2012-10-22 EP EP12787388.3A patent/EP2776394B1/en active Active
- 2012-10-22 CN CN201280051318.1A patent/CN103958474B/zh active Active
- 2012-10-22 CA CA2849564A patent/CA2849564C/en active Active
- 2012-10-22 IL IL264982A patent/IL264982B/en unknown
- 2012-10-22 CN CN201710065025.3A patent/CN107417549A/zh not_active Withdrawn
- 2012-10-22 SG SG11201401066PA patent/SG11201401066PA/en unknown
- 2012-10-22 JP JP2014536287A patent/JP6046154B2/ja active Active
- 2012-10-22 US US14/352,719 patent/US9469597B2/en active Active
- 2012-10-22 MY MYPI2014001153A patent/MY187638A/en unknown
- 2012-10-22 SM SM20190137T patent/SMT201900137T1/it unknown
- 2012-10-22 RU RU2014119976A patent/RU2668952C2/ru active
- 2012-10-22 IN IN3337CHN2014 patent/IN2014CN03337A/en unknown
- 2012-10-22 BR BR112014009238-9A patent/BR112014009238B1/pt active IP Right Grant
- 2012-10-22 AU AU2012324805A patent/AU2012324805B2/en active Active
- 2012-10-22 EP EP18214953.4A patent/EP3495349B1/en active Active
- 2012-10-22 WO PCT/EP2012/070900 patent/WO2013057322A1/en not_active Ceased
- 2012-10-22 EP EP22155976.8A patent/EP4074695A1/en not_active Withdrawn
-
2014
- 2014-03-19 ZA ZA2014/02022A patent/ZA201402022B/en unknown
- 2014-04-08 CR CR20140166A patent/CR20140166A/es unknown
- 2014-05-20 CO CO14108123A patent/CO6960552A2/es not_active Application Discontinuation
-
2016
- 2016-03-28 IL IL244782A patent/IL244782A0/en unknown
- 2016-09-01 US US15/254,020 patent/US9670136B2/en active Active
- 2016-11-16 JP JP2016222911A patent/JP2017075155A/ja not_active Withdrawn
-
2017
- 2017-04-26 US US15/497,556 patent/US10214477B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015502335A5 (cg-RX-API-DMAC7.html) | ||
| RU2014119976A (ru) | (гетеро)арилциклопропиламины в качестве ингибиторов lsd1 | |
| HRP20140970T1 (hr) | Spoj azolkarboksamida ili njegova sol | |
| JP5586484B2 (ja) | ピロリジン誘導体 | |
| AR089134A1 (es) | Arilos y heteroarilos biciclicos inhibidores de los canales de sodio | |
| JP2012507566A5 (cg-RX-API-DMAC7.html) | ||
| JP2013505903A5 (cg-RX-API-DMAC7.html) | ||
| JP2006515858A5 (cg-RX-API-DMAC7.html) | ||
| JP2019521109A5 (cg-RX-API-DMAC7.html) | ||
| JP2019517487A5 (cg-RX-API-DMAC7.html) | ||
| JP2012510989A5 (cg-RX-API-DMAC7.html) | ||
| CA2482346A1 (en) | Substituted phenylacetamides and their use as glucokinase activators | |
| RU2018145761A (ru) | Сульфонамидное соединение или его соль | |
| SI2824100T1 (en) | 1,2,5-oxadiazoles as inhibitors of indolamine 2,3-dioxygenase | |
| RU2017121044A (ru) | Производные амидотиадиазола в качестве ингибиторов надфн-оксидазы | |
| JP2006524222A5 (cg-RX-API-DMAC7.html) | ||
| JP2017533968A5 (cg-RX-API-DMAC7.html) | ||
| JP2017502994A5 (cg-RX-API-DMAC7.html) | ||
| RU2019133530A (ru) | ПРОИЗВОДНЫЕ АМИДА В КАЧЕСТВЕ БЛОКАТОРОВ Nav1.7 И Nav1.8 | |
| JP2012502986A5 (cg-RX-API-DMAC7.html) | ||
| JP2018500351A5 (cg-RX-API-DMAC7.html) | ||
| CA2568608A1 (en) | Six membered amino-amide derivatives as angiogenesis inhibitors | |
| JP2013541536A (ja) | ピリミジン誘導体の製造プロセス | |
| RU2014113679A (ru) | N-(2-амино-6,6-дифтор-4,4а,5,6,7,7а-гексагидро-циклопента[e][1,3]оксазин-4-ил)-фенил)-амиды в качестве ингибиторов бета-секретазы 1 | |
| JP2017508795A5 (cg-RX-API-DMAC7.html) |